Precigen (NASDAQ:PGEN) Trading 8.4% Higher - Should You Buy?

Precigen, Inc. (NASDAQ:PGEN - Get Free Report)'s stock price shot up 8.4% on Tuesday . The stock traded as high as $2.03 and last traded at $2.13. 502,453 shares were traded during trading, a decline of 77% from the average session volume of 2,153,742 shares. The stock had previously closed at $1.96.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PGEN. JMP Securities reiterated a "market outperform" rating and set a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and set a $6.00 target price (up from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $7.00.

Precigen Stock Down 3.0 %

The company has a market cap of $559.38 million, a P/E ratio of -3.47 and a beta of 1.66. The firm has a 50 day moving average of $1.28 and a 200-day moving average of $1.06.

Institutional Investors Weigh In On Precigen

Large investors have recently modified their holdings of the business. BNP Paribas Financial Markets bought a new stake in shares of Precigen in the 4th quarter valued at about $27,000. Stifel Financial Corp raised its holdings in shares of Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 15,680 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 5,915 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Precigen in the 4th quarter valued at about $35,000. Finally, SG Americas Securities LLC boosted its position in Precigen by 44.2% during the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 13,823 shares in the last quarter. Institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.